This database contains 1058 studies, archived under the term: "aged"
Click here to filter this large number of results.
Efficacy of rivastigmine on executive function in patients with Parkinson’s disease dementia
Background and Objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures […]
A memory and organizational aid improves Alzheimer disease research consent capacity: results of a randomized, controlled trial
Rubright, Jonathan,
Sankar, Pamela,
Casarett, David J.,
Gur, Ruben,
Xie, Sharon X.,
Karlawish, Jason
Objectives: Early and progressive cognitive impairments of patients with Alzheimer disease (AD) hinder their capacity to provide informed consent. Unfortunately, the limited research on techniques to improve capacity has shown mixed results. Therefore, the authors tested whether a memory and organizational aid improves the performance of patients with AD on measures of capacity and competency […]
Sleep in dementia caregivers and the effect of a nighttime monitoring system
Purpose: The purpose of this study was to determine if a nighttime home monitoring system, designed to track the movements of a care recipient with dementia, would relieve worry and improve sleep in caregivers of persons with dementia.; Design and Methods: In this controlled clinical trial, 49 dementia caregivers were followed for up to 1 […]
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Weintraub, Daniel,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one […]
Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size
Román, Gustavo C.,
Salloway, Stephen,
Black, Sandra E.,
Royall, Donald R.,
DeCarli, Charles,
Weiner, Michael W.,
Moline, Margaret,
Kumar, Dinesh,
Schindler, Rachel,
Posner, Holly
Background and Purpose: We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria.; Methods: This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 […]
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
Quinn, Joseph F.,
Raman, Rema,
Thomas, Ronald G.,
Yurko-Mauro, Karin,
Nelson, Edward B.,
van Dyck, Christopher,
Galvin, James E.,
Emond, Jennifer,
Jack, Clifford R., Jr.,
Weiner, Michael,
Shinto, Lynne,
Aisen, Paul S
Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.; Objective: To determine if supplementation with DHA slows cognitive and functional decline […]
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]